Premium
Decitabine and venetoclax for IDH1/2 ‐ mutated acute myeloid leukemia
Author(s) -
Venugopal Sangeetha,
Maiti Abhishek,
DiNardo Courtney D.,
Loghavi Sanam,
Daver Naval G.,
Kadia Tapan M.,
Rausch Caitlin R.,
Alvarado Yesid,
Ohanian Maro,
Sasaki Koji,
Short Nicholas J.,
Takahashi Koichi,
Yilmaz Musa,
Ravandi Farhad,
Kantarjian Hagop M.,
Konopleva Marina Y.
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26122
Subject(s) - venetoclax , decitabine , medicine , idh1 , azacitidine , myeloid leukemia , isocitrate dehydrogenase , idh2 , gastroenterology , oncology , refractory (planetary science) , myeloid , febrile neutropenia , neutropenia , leukemia , chemotherapy , biology , gene expression , chronic lymphocytic leukemia , dna methylation , mutation , gene , biochemistry , astrobiology , enzyme